Palisade Bio Income from Discontinued Operations 2010-2025 | PALI

Palisade Bio income from discontinued operations from 2010 to 2025. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.

Palisade Bio Income from Discontinued Operations 2010-2025 | PALI

Palisade Bio income from discontinued operations from 2010 to 2025. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$213.1B
Amgen (AMGN)$159.1B
Gilead Sciences (GILD)$134.7B
Vertex Pharmaceuticals (VRTX)$117.7B
Bristol Myers Squibb (BMY)$95B
CSL (CSLLY)$81.2B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$58.9B
Alnylam Pharmaceuticals (ALNY)$41.8B
Argenex SE (ARGX)$34.6B
BioNTech SE (BNTX)$26.2B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.5B
Biogen (BIIB)$18B
Illumina (ILMN)$15B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$13.9B
Incyte (INCY)$13B
Exelixis (EXEL)$12.1B
Moderna (MRNA)$12B
BioMarin Pharmaceutical (BMRN)$10.8B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.3B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$7.9B
Roivant Sciences (ROIV)$7.8B
Legend Biotech (LEGN)$7.8B